

Investor Service Announcement no. 6/2007

To: OMX Nordic Exchange

Hørsholm, Denmark, September 11, 2007

LifeCycle Pharma to Webcast Presentation at G5: ThinkEquity Partners 5th Annual Growth Conference

Summary: LifeCycle Pharma to Webcast Presentation at G5: ThinkEquity Partners 5th Annual Growth Conference

Hørsholm, Denmark, September 11, 2007; LifeCycle Pharma A/S (OMX:LCP), an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in large therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, including recently Food and Drug Administration approved LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, announced today that Flemming Ornskov, President and Chief Executive Officer, is scheduled to give a company presentation at the G5: ThinkEquity Partners 5th Annual Growth Conference on Thursday, September 20, 2007 at 10:00 a.m. PDT (1:00 p.m. in New York; 7:00 p.m. in Denmark) at the St. Regis Hotel in San Francisco, CA.

A live webcast of Flemming Ornskovs presentation will be accessible via the Company's web site at www.lcpharma.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. A replay of the webcast will become available approximately 1 hour after the conclusion of the live presentation and will be accessible for 30 days.

About LifeCycle Pharma A/S ("LCP"):

LCP, headquartered in Hørsholm, Denmark, is an emerging specialty pharmaceutical company focused on developing and commercializing a portfolio of innovative products in therapeutic areas such as cholesterol management, hypertension, organ transplantation and autoimmune diseases. LCP's proprietary MeltDose® technology, offers lower dosing, reduced side effects, improved safety and patient compliance, and reduced product development costs and times. LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, is LCP's first FDA approved product (approved in August 2007). LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX:LCP). For further information, please visit www.lcpharma.com.

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

Page 1 of 2

Investor Service Announcement no. 6/2007

Contact:

Francesca M. DeMartino

Director, Investor Relations & Corporate Communications

(201) 633-4729; FDM@lcpharma.com

---oo0oo---

